This article is more than 5 years old. Information may no longer be current.

Oxurion completes enrollment in plasma kallikrein inhibitor trial

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Oxurion NV has completed enrollment in a phase 1 study of its plasma kallikrein inhibitor for treatment of diabetic macular edema, according to a press release.

The safety of a single intravitreal injection of THR-149 will be evaluated in 15 patients with visual impairment due to center-involved DME. Three ascending dose levels will be used.

“We are delighted to have completed patient recruitment in this important clinical trial earlier than anticipated,” Oxurion CEO Patrik De Haes, MD, said. “This study has been designed to assess THR-149's safety profile and to provide the information needed to plan the future clinical development plan of this novel plasma kallikrein inhibitor for the treatment of DME.”